Breaking News

Xencor Receives Janssen R&D Milestone

January 17, 2013

Will use Xtend technology for therapeutic antibody

Xencor, Inc. has received a milestone payment from Janssen R&D for the use of Xencor's Xtend half-life extension technology in a therapeutic antibody. The companies had entered a technology license agreement in 2009. The antibody target and payment amount were not disclosed.
 
"There has been significant interest in Xtend technology because of the impact it has on the pharmacokinetic properties of antibodies, and we are seeing Xencor technology license agreements with partners translate into promising pipeline programs," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.